Vmbook Online ordering

Genvec Inc

GenVec, Inc. was a biopharmaceutical company focused on the development of novel therapies and vaccines to protect against infectious diseases and treat cancer. The company used its proprietary, non-viral Gene Transport System (GTS) technology to develop therapies and vaccines that were designed to allow physicians to target a wide range of diseases at the genetic level. GenVec was a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol "GNVC."

GenVec was founded in 1991 and was based in Gaithersburg, Maryland. The company had a diverse pipeline of product candidates in various stages of development, including programs in clinical trials for the treatment of diseases such as respiratory syncytial virus (RSV) infection, cytomegalovirus (CMV) infection, and ocular herpes simplex virus (HSV) infection. GenVec also had programs in preclinical development for the treatment of other infectious diseases, such as influenza and hepatitis C, as well as for the treatment of cancer.

However, it's important to note that GenVec is no longer a publicly traded company. In 2017, GenVec announced that it had entered into a merger agreement with Novartis AG, a multinational pharmaceutical company. As a result of the merger, GenVec became a wholly owned subsidiary of Novartis and was delisted from the NASDAQ stock exchange. As of my knowledge up to 2021, GenVec continues to operate as a subsidiary of Novartis, focusing on the development of novel therapies and vaccines.